Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID, 1298,"Nordquist N, et al., J Autoimmun 2000 Dec;15(4):425-32.",joint integrity trait,,RS:0000384,DXE3/Ztm,both,0 days,29,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,3,%,,,MMO:0000163,in vivo visual assessment,,9504000.0,,,,,pristane (150 ul) (for 110 days),70142,pristane (150 ul) (for 110 days) 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000384,DXE3/Ztm,both,98 days to 56 days,20,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,10,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69667,pristane (150 ul) 1298,"Nordquist N, et al., J Autoimmun 2000 Dec;15(4):425-32.",joint integrity trait,,RS:0000384,DXE3/Ztm,both,0 days,1,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,43,d,,,MMO:0000163,in vivo visual assessment,,9504000.0,,,,,pristane (150 ul) (for 110 days),70145,pristane (150 ul) (for 110 days) 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000384,DXE3/Ztm,both,98 days to 56 days,20,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,32,d,3.3541,15.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69675,pristane (150 ul) 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000384,DXE3/Ztm,both,98 days to 56 days,20,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69683,pristane (150 ul)